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Abstract
Modified vaccinia virus Ankara (MVA) has become a promising vaccine vector due to its immunogenicity and its
proven safety in humans. As a general approach for stringent and rapid selection of recombinant MVA, we
assessed marker rescue of the essential viral D4R gene in an engineered deletion mutant that is fully replication
defective in wild-type cells. Recombinant, replicating virus was obtained by re-introduction of the deleted viral
gene as a dominant selection marker into the deletion mutant.
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Introduction
Modified vaccinia virus Ankara (MVA) was developed as
a safer smallpox vaccine during the smallpox eradication
campaign [1]. For this purpose, vaccinia strain Ankara
was passaged more than 500 times in primary chicken
embryo fibroblast cells (CEF). Replication of MVA is
almost completely restricted to avian cells, and the virus
is strongly attenuated in vivo. The excellent safety
record of this strain was established in vaccination cam-
paigns in the 1970’s, when over 120,000 humans includ-
ing immune suppressed individuals were immunized
[2,3]. Safety of MVA as a smallpox vaccine has also
been addressed by others in clinical studies [4-6].
The attenuated phenotype is the consequence of mul-
tiple changes in the viral genome. Six major deletions
and numerous other mutations including small dele-
tions, point mutations and insertions relative to the par-
ental strain were mapped [7,8]. MVA has been
intensively studied as a vector for use in recombinant
live vaccines [9]. MVA-based live vaccines have already
been under evaluation in numerous clinical trials,
recently for instance for HIV [10,11], influenza [12], and
against smallpox [5]. Safety was also demonstrated with
a recombinant MVA-based cancer vaccine (TroVax) in
clinical studies [13].
Recombinant MVA are usually generated by homolo-
gous recombination techniques [14,15], followed by
repeated rounds of plaque purification under selective
conditions. Methods for clonal selection have been
established previously for vaccinia virus in general,
including dominant E. coli gpt marker selection [16]
and lacZ color screening [17], and are equally used for
work with MVA. Other techniques for the isolation of
recombinant vaccinia virus (VV), such as tk
- selection,
c a n n o tb ea p p l i e dt oM V Ad u et oi t sr e s t r i c t i o nt oa
few cell types. Specifically for MVA, certain host range
selection methods have been developed that make use
of the genetic basis of the growth restrictions of MVA.
For example, introduction of the VV gene K1L as a
marker which is naturally deleted in MVA, extends the
host range to rabbit kidney cells [18]. However, there
might be regulatory concerns that selection markers can
change the attenuated phenotype of MVA thereby
impairing the well-established safety profile of MVA.
For instance, the VV K1L gene encodes viral functions
that impair important anti-viral defense mechanisms of
the infected host. The K1L gene product suppresses
activation of the transcription factor NF-B[ 1 9 ] .M o r e
recently, it was shown that K1L -alongside with C7L- is
also involved in preventing RNA-activated protein
kinase (PNK) -dependent and -independent shut-off of
protein synthesis by the infected host [20]. In MVA, the
lack of a functional K1L gene enables early-phase PNK-
mediated host responses possibly contributing to both
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of the immune response [21].
Generally, plaque purification procedures are more
difficult with MVA compared to replicating vaccinia
strains, because MVA work is limited to a narrow range
of cell substrates. Classically, MVA is grown and puri-
fied on primary CEF. Plaque formation on these cells is
not as clear as with most permanent cell lines, and the
work depends on cell supply of constant quality. To
compensate for these shortcomings, additional detection
methods such as immunostaining have been applied for
MVA plaque isolation on CEF [22].
An elegant and stringent selection approach is the res-
cue of virus with wild-type (wt) -like growth properties
by re-introduction of a previously deleted viral function.
For MVA, deletion of the non-essential genes E3L and
F13L, respectively [23,24] resulted in viruses of altered
plaque properties or narrowed host range, allowing the
selection of recombinants after re-introduction of these
genes and rescue of the wild-type phenotype.
While the latter selection methods are based on non-
essential host range genes, we now attempted a rescue
selection procedure by use of a parental MVA that lacks
an essential function and that is entirely growth incom-
petent on wild-type cells. Deletion of the essential gene
D4R from vaccinia virus and complementation of the
deleted viral function by an engineered complementing
cell line has been described earlier [25]. The vaccinia
virus gene D4R encodes the protein uracil DNA glycosy-
lase, which catalyzes the removal of uracil residues from
double-stranded DNA, and which is an indispensable
component of the vaccinia DNA polymerase complex
[26]. Recently, knock-out of the D4R gene has been
applied to MVA with the purpose of reduced vector
antigen expression in recombinant vaccines [27].
Growth of the knock-out virus requires a permanent
cell-line that may be engineered to complement the
viral function. For MVA which is largely restricted to
avian cells, the avian cell line DF-1 was found to be
appropriate for this task. The cell line DF-1 had been
created after spontaneous immortalization of CEF and
was initially investigated for the work with avian retro-
viruses [28]. Because D4R-based dominant host range
selection was found to provide a powerful selection
method for replicating vaccinia recombinants [29], it
was now attempted to adopt this technique also to
MVA.
Materials and methods
Cell lines and viruses
The African green monkey cell line Vero (ATCC CCL-
81), and the chicken embryo fibroblast cell line DF-1
(ATCC CCL-12203) were grown in DMEM (Biochrom)
containing 5% of fetal calf serum (PAA), non-essential
amino acids (NEAA) and Pen/Strep (Lonza). Primary
chicken embryo cells (CEF) were isolated from 12 day
old chicken embryos and grown in Med-199 (Gibco)
containing 5% of fetal calf serum, Pen/Strep and NEAA.
Construction of the D4R defective vaccinia virus Lister
(dVV-L) is described elsewhere [30]. Modified vaccinia
virus Ankara (Isolate MVA74 LVD6) was obtained from
Dr. Bernard Moss, National Institute of Allergy and
Infectious Diseases. This MVA isolate originates from
three rounds of plaque purifications of MVA passage
572 [1] and was frozen prior to the emergence of bovine
spongiform encephalopathy. The virus rMVA-YF/d3
that carries the YFV prME cassette in the genomic del3
region is described elsewhere [31].
Retroviral transduction of DF-1 cells
The D4R gene was introduced into DF-1 cells by trans-
duction with a retroviral vector that had been derived
from the commercially available vector pLXSN, Invitro-
gen [32]. Retroviral vector particles were generated in
Vero cells by simultaneous transfection with the packa-
ging plasmids pGAGPOL-gpt [33] and pALF (both
kindly provided by W. Günzburg, University of Veterin-
ary Medicine Vienna), and the vector plasmid pLXSN-
D4R [34]. The plasmids (7 μg each) were transfected
into subconfluent Vero cells by calcium phosphate
transfection as described before [35]. After 2 days, the
supernatant was collected, supplemented with 4 μg/ml
polybrene and filtered through 0.45 μm filters (VWR).
The retroviral vector containing supernatant was diluted
1:10 and used to infect DF-1 cells of passage 31. After 4
days, cells were split into medium containing 100 μg/ml
G418 (Invitrogen). Media changes were made every 4
days until cell foci could be picked and expanded under
continued selective pressure. In passage 38, a master cell
bank of cDF-1 was frozen, of which one aliquot was
thawed and expanded for a working cell bank. The
working cell bank corresponds to passage 41 of the par-
ental DF-1 line.
Construction of plasmids
pDM-Zgpt
The plasmid pDM-Zgpt contains the lacZ/gpt double
marker cassette flanked by genomic sequences of MVA
to drive homlogous recombination into the viral D4R
locus. First, the MVA sequences, that flank the D4R
gene at either side, were amplified by PCR, using MVA
genomic DNA as the template. The left flanking region
of the D4R gene was amplified using the forward primer
5’-CAT TGT TAA CTG TGA GCT ACT GTA GGT
G-3’ and the reverse primer 5’-C T CG A GG T CG A C
AAG CTT CCA TGG TTA TAT CAA ATT AGA TAC
C-3’. For cloning purposes, a HpaI restriction site
(restriction sites underlined) was introduced into the
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SalI, HindIII and NcoI as a future multiple cloning site.
The MVA D4R right flank was generated by PCR with
the forward primer 5’-GTC GAC CTC GAG GGC GCC
GCG GCC GCT GCT TTA GTG AAA TTT TAA C-3’
containing the restriction sites SalI, XhoI, EheI, NotI,
and the reverse primer 5’-CGT AAG CGG AAG AGC
ACT ATT GTT GTT CAT ATC CAC G-3’.T h eP C R
products were sequentially cloned into pPCR-Scrip-
tAmpSK(+) (Stratagene). In the resulting construct
pDM, the MVA D4R flanks (left flank: 836 bp; right
flank: 685 bp) frame a multiple cloning site. Next, the
lacZ/gpt double marker cassette from pDW-2 [29] was
cloned via HindIII/SalI restriction into pDM to generate
pDM-Zgpt.
pDM-D4R
T h eM V AD 4 Rg e n ew a sa m p l i f i e db yP C Rf r o mM V A
genomic DNA with the forward primer 5’-AGG CGT
TTG TAT TCG CTT GG-3’, and the reverse primer 5’-
ACA CCA TGG GCT AGC TCG CGA TTA ATA AAT
AAA CCC TTG AGC C-3’. The forward primer binds
to the genomic MVA DNA upstream of an Eco105I site
that is located 27 bp outside of the the D4R gene. The
reverse primer contained the restriction sites NcoI, NheI
and NruI for a MCS downstream of the D4R gene.
Using the restriction sites Eco105I and NcoI, the PCR
product was cloned into pDM resulting in pDM-D4R.
pDM-D4R-YF
To construct the plasmid for integration of the YFV
prME into the D4R/D5R locus, the yellow fever prME
gene cassette was excised from plasmid pd3-YFprMEco
a n dc l o n e di n t op D M - D 4 R ,u s i n gt h er e s t r i c t i o ns i t e s
NheI and SalI. The resulting plasmid pDM-D4R-YF
contains the YFV prME expression cassette downstream
of the D4R gene [31].
Generation of viruses
Recombinant virus was generated by homologous
recombination [15]. Confluent monolayers of the indi-
cated cell types were infected/transfected according to
the procedures essentially described before [34].
dMVA-ZG
Infection/transfection with MVA-wt and the plasmid
pDM-Zgpt was done in CEF. Recombinant MVA was
selected by seven rounds of plaque purification with gpt
selection [16] and lacZ screening [17] in the D4R com-
plementing cell line cDF-1. A plaque isolate that did not
show any growth on wt DF-1 cells was expanded in
cDF-1 and a purified virus stock was prepared as pre-
viously described [36]. The resulting defective MVA was
termed dMVA-ZG.
rMVA-YF/D4
Wild type DF-1 cells were infected with dMVA-ZG, and
the plasmid pDM-D4R-YF was used for transfection.
Plaque purification and amplification were carried out
in wild type DF-1 cells.
Characterization of defective MVA by PCR
PCR was performed to confirm the expected genomic
structure of the defective virus dMVA-ZG and to test
for contamination with residual wild-type MVA. For
this purpose, sucrose cushion purified dMVA-ZG stock
was used. For spike controls, 1%, 0.1%, 0.01% and
0.001% MVA-wt were added to dMVA-ZG samples.
After digestion with 0.5 μg/μl proteinase K (Sigma) for
3 hrs at 56°C and 2 hrs at 95°C, 1 μl samples corre-
sponding to 1 × 10
5 pfu were subjected to PCR.
The reaction was carried out with the primers 5’-ACC
TTC CAA CTG TGG ATA CTC TG-3’ and 5’-TCG
AAT GAA ATA AAC CCT GGT-3’ resulting in a PCR
signal of 2430 bp with MVA-wt, and of 5624 bp with
dMVA-ZG as a template.
Growth experiments with MVA and vaccinia virus
Confluent cells cultivated in 6-well plates were infected
with 5 × 10
4 tissue culture infectious doses 50%
(TCID50) of the respective MVA or vaccinia virus, fol-
lowed by media change after 1 h. Cells were kept in a
CO2 incubator at 37°C. At the respective time points
post infection, cells were scraped into the medium and
disrupted by three cycles of freeze/thaw and ultrasonica-
tion. The virus titer was determined by TCID50 assay,
and the output/input ratio was calculated. MVA was
grown and titrated on the cell line DF-1, and dMVA-
ZG on the complementing cell line cDF-1.
Determination of infectious titers
Infectious titers were assayed by TCID50 assay. Serial
ten-fold dilutions of specimen were applied to CEF in
96-well plates, and virus induced cytopathic effect was
evaluated by light microscopy after 5-7 days of incuba-
tion at 37°C in a CO2 atmosphere. Viral titers were cal-
culated according to the formula of Spearman and
Kaerber [37] and were expressed as TCID50/ml. One
TCID50/ml corresponds to about 0.5 plaque forming
unit (pfu), as determined in a series of parallel
measurements.
Double immunostaining
Plaques of MVA that express YFV prME antigen were
identified by double immunostaining.
cDF-1 cells were infected with recombinant YF prME-
expressing MVA for a period of 4 days, and were then
fixed with methanol/acetone (1:1). To detect plaques of
YFV prME expressers, a guinea pig antiserum against
YFV-17D (Lot # 070824/T4, Baxter) was used. Goat
anti-guinea pig horseradish peroxidase-conjugated IgG
(Jackson ImmunoResearch Laboratories, Inc.) was used
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diaminobenzidine (DAB) solutions including nickel
(Vector Laboratories), resulting in black plaques. In a
subsequent round, plaques were additionally stained for
vaccinia antigens, using a polyclonal rabbit anti-vaccinia
virus serum (Lot no. VVSKP26012006, Baxter). In this
case, the secondary antibody was a goat anti-rabbit per-
oxidase-conjugated IgG (Jackson Inc), and staining was
done with DAB solution without nickel, resulting in
brown plaques, essentially as described earlier [38].
Growth assay of defective MVA for replicating
contaminants
To detect replication competent virus in defective virus
stocks, ten 175 cm
2 cell culture flasks of confluent DF-1
cells were infected with a total of 2 × 10
6 pfu (moi =
0.05) of dMVA-ZG. In parallel cell culture flasks were
infected with 100 pfu wild-type MVA or with a mixture
of 2 × 10
6 pfu dMVA-ZG and 100 pfu wild-type MVA
to control the sensitivity of detection. Uninfected DF-1
cells served as a negative control. Five days post infec-
tion plaques of residual replication competent virus
were visualized by crystal violet staining.
Western blotting
Whole cell lysates were prepared from 5 × 10
6 infected
cells by three cycles of freezing/thawing, followed by
ultrasonication and denaturation in protein loading buf-
fer (Fermentas). Aliquots corresponding to 1 × 10
5 cells
were resolved by 12% polyacrylamide gel electrophoresis.
Blotting was performed essentially as described pre-
viously [39]. For detection, a polyclonal guinea pig anti-
serum (Lot # 070824/T4, Baxter) against YFV-17D, and
anti-guinea pig alkaline phosphatase-conjugated immu-
noglobulin (Sigma) as the second antibody, were used.
Isolation of genomic DNA and real-time PCR
Recombinant virus plaques were picked and suspended
in 500 μl DMEM, and used to infect cDF-1 cells in 6-
well plates to amplify the recombinant virus and poten-
tial residual parental dMVA in the stocks. As controls,
cells were infected in parallel with the parental dMVA-
ZG, wild-type MVA and rMVA-YF/del3. After 5 days,
infected cells were harvested, and genomic DNA was
isolated using DNeasy kit (Quiagen Inc.). Aliquots corre-
sponding to 0.4% of the 1 ml harvest from a 6-well were
used as template in quantitative PCR reactions. Real-
time PCR was performed with 2 μl of genomic template
DNA in a total volume of 20 μlu s i n gT a q m a ng e n e
expression master mix (Applied BioSystem), and primers
and probes at a final concentration of 900 nM and 200
nM, respectively, using a StepOnePlus real time PCR
system (ABI, 4376598).
For amplification of the individual genomic targets,
the following primer-probe sets were used:
YFV prME-specific: FWD (5’-TGA TGC AGG TCA
AAG TGT CTA AGG-3’), RWD (5’-TGT TGA
T G GC G GC T GT C A - 3 ’); and Probe (5’-6FAM-
CTG CCG GAT CCC CGT-MGB-3’).
LacZ-specific: FWD (5’-ATT CAG GCT GCG CAA
CTG TT-3’), RWD (5’-CAG CAC ATC CCC CTT
TCG-3’), and Probe (5’-6FAMAAG GGC GAT CGG
TGC G-MGB-3’).
MVA 173R gene-specific: FWD (5’-GCA ACG GCG
AAA CAA AAT ATT T-3’), RWD (5’-ATT AGG
ACA CGT AAC AGT ATC ATT CCA-3’), and
Probe (5’-6FAM-TTG CGA AGA AAA AAA TGG
AA-MGB-3’).
Specific for plasmid DNA (Amp
r gene): FWD (5’-
CCA ACG ATC AAG GCG AGT TAC-3’),
qPCRVVamp-RWD (5’-CCG AAG GAG CTA ACC
GCT TT-3’), and Probe (5’-6FAM-TGA TCC CCC
ATG TTG TG-MGB-3’).
To generate standard curves for determination of
genomic equivalents, plasmids containing Amp
r -, lacZ
and 173R sequences and a plasmid containing the YFV
prME gene, were used in ten-fold dilutions ranging
from 1 × 10
8 to 1 × 10
3 DNA copies.
Results and discussion
Generation of the D4R complementing cell line cDF-1
Traditionally, MVA is propagated in primary CEF. In
order to propagate the D4R-deleted MVA that should
serve as the parental strain for the intended selection
procedure, a stably D4R-expressing cell line was
required. Ideally, the cell line should be non-tumori-
genic and of avian origin to allow the growth of MVA.
For technical reasons, formation of clear MVA plaques
is a desirable general characteristic of the cell line of
choice. To evaluate the cell line DF-1 for the intended
selection of recombinant replicating MVA, we assessed
it for propagation of MVA using primary CEF as a
reference. In DF-1, a maximal MVA titer (about 7.4
log10 TCID50) was reached as early as day 1. In plaque
assays, MVA formed confined, circular plaques on DF-1
cells, making this cell line useful for the intended plaque
purification of defective MVA.
The D4R complementing DF-1 based cell line was
generated by retroviral transduction analogous to a
Vero-based complementing cell line described previously
[34]. We used the D4R-defective vaccinia virus Lister
dVV-L [30] to screen for the cell clone that complemen-
ted most efficiently the lacking viral function. The DF-1
cell clone #4A allowed amplification of the defective
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was therefore further expanded to obtain the cell line
cDF-1.
Generation of a non-replicating parental virus
In order to knock out the essential vaccinia gene D4R,
and to prepare a growth defective MVA, a recombina-
tion plasmid (pDM-Zgpt) was constructed that contains
the MVA genomic regions that naturally flank the MVA
D4R gene with the D4R sequences being deleted. The
D4R gene and its natural promoter were replaced by a
marker cassette encoding the E. coli lacZ and gpt genes
(Figure 1a). After infection with MVA and transfection
with the plasmid pDM-Zgpt, the intended recombinant
virus dMVA-ZG was isolated by repeated rounds of pla-
que purification under gpt selection combined with blue
plaque screening in the complementing cell line cDF-1.
The virus dMVA-ZG did not form plaques on wt DF-1
cells (Figure 2c), while it readily formed plaques on the
complementing cell line cDF-1 (Figure 2a). Plaque for-
mation by dMVA-ZG was also absent in CEF (not
shown). As expected, the MVA-wt strain grew both on
cDF-1 and DF-1 cells (Figure 2b, d). On cDF-1 cells, the
defective virus propagated similar to MVA-wt, while in
the absence of complementation, titers decreased by
about 100-fold within 4 days, indicating that the virus
was completely growth negative in wt cells (Figure 3).
The defective virus dMVA-ZG is free of MVA-wt
The absence of replicating contaminants from the
dMVA-ZG stock was of special interest because the
reconstitution of growth should serve as the key selec-
tion criterion for further recombinants in the dominant
host range selection procedure. To phenotypically verify
the absence of replicating MVA, a growth assay on DF-
1 was performed that was capable to detect 1 pfu repli-
cating MVA in 2 × 10
7 pfu of dMVA-ZG. No plaques
were detectable after a 5 days incubation further
demonstrating the purity of the preparation.
The absence of D4R containing wild type contami-
nants in the dMVA-ZG stock was also demonstrated by
PCR. Primers were designed that bind to the viral geno-
mic sequences flanking the D4R gene, resulting in a
ƉDͲŐƉƚ
ƉDͲϰZͲz&
DsͲǁƚ
ĚDsͲ'


ϯZ ϱZ
ϯZ
ϱZ
ϱZ
ϯZ ϰZ
ϯZ ϱZ
ϰZ
Figure 1 Outline of the D4R-dominant host range selection
system. a. Schematic representation of the plasmid pDM-Zgpt for
the construction of the D4R-deleted dMVA-ZG, and the
corresponding insertion locus in the genome of MVA. b. Plasmid
pDM-D4R-YF and the defective parental virus dMVA-ZG. MVA
sequences are represented by boxes. The MVA genes D3R, D4R, D5R
are marked grey. Foreign genes cassettes inserted into MVA are
symbolized by hatched boxes. Arrows indicate the binding sites of
the PCR primers that were used for confirmation of the structure
and purity of dMVA-ZG.
Figure 2 Plaque formation of dMVA-ZG and wild-type MVA in
avian DF-1 cells. cDF-1 (a, b) and wild-type DF-1 (c, d) cells were
infected with 100 pfu/well of dMVA-ZG (a, c) or MVA-wt (b, d). Four
days post infection, immunostaining was performed with anti-
vaccinia virus antibodies. Photographs show immune-stained
plaques.
Figure 3 Growth kinetics of MVA and dMVA-ZG.c D F - 1c e l l s
were infected with the defective virus dMVA-ZG at moi = 0.05. For
comparison, infections of DF-1 cells dMVA-ZG and with wild-type
MVA were performed in parallel. Cells were harvested at the
indicated time points and the viral titers were determined by TCID50
titration. Mean values ± SEM are shown (n = 6).
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genomic DNA as the template. In order to avoid false
positive signals resulting from viral sequences on the
plasmid used for recombination, the chosen binding
s i t e so ft h ep r i m e r sa r el o c a t e do u t s i d et h eV V
sequences in the plasmid pDM-Zgpt (see Figure 1).
With dMVA-ZG that contains the larger marker cas-
sette in place of the D4R gene, a PCR fragment of 5624
bp was amplified (Figure 4). Due to the preferred ampli-
fication of smaller fragments in PCR reactions, down to
0.01% MVA-wt spiked into dMVA-ZG stock could be
detected as an additional band (Figure 4, lane 7). No wt
DNA was detected in the dMVA-ZG stock confirming
therefore the purity of the defective virus.
Generation of recombinant MVA by rescue of the D4R
gene
For the generation of MVA recombinants with restored
replication, we constructed the basic recombination
plasmid pDM-D4R. This plasmid contains the D4R gene
in its natural genomic context, with an additional multi-
ple cloning site (MCS) for the insertion of genes of
interest between the D4R and the D5R gene. Introduc-
tion of foreign genes into the D4R/D5R intergenic
region was described earlier for recombinant vaccinia
virus [29]. The genomic sequence adjacent to the D4R
gene is highly conserved among vaccinia strains, sug-
gesting that also in MVA, insertions in the D4R/D5R
locus should not significantly interfere with virus viabi-
lity. As proof of concept, we constructed the plasmid
pDM-D4R-YF (Figure 1b) by placing an expression cas-
sette for the yellow fever virus (YFV) surface proteins
(prME) into the MCS of the basic recombination vector.
Using this recombination plasmid together with the
defective parental virus dMVA-ZG, we attempted the
generation of a replication competent, YFV antigen-
expressing MVA, termed rMVA-YF/D4. The design of
the expression cassette containing the YFV prME
sequence is described elsewhere [31].
Infection/transfection for homologous recombination
between the defective MVA and the recombination plas-
mid pDM-D4R-YF and all subsequent steps were per-
formed in the wt DF-1 cell line. Virus was harvested 2
days later and plated onto fresh cells under agarose
overlay in the absence of selective agents. After 3 days,
neutral red and X-Gal staining revealed clearly visible
plaques of wild-type size. In this first round of plaque
purification, already 70% of the plaques were no longer
stainable by X-Gal, indicating the absence of parental b-
galactosidase (b-Gal)-expressing dMVA-ZG virus.
Twelve white plaques were randomly picked from this
first round of plating, and were checked for absence of
Figure 4 PCR analysis of the D4R deletion in the defective virus dMVA-ZG. Genomic DNA of dMVA-ZG was subjected to PCR amplification
using a primer pair that frames the D4R deletion (Lane 5). Negative controls were run without any template (Lane 2), with uninfected cDF-1
(Lane 3) cells and with the recombination plasmid pDM-Zgpt (Lane 4). Spike controls were performed with dMVA-ZG containing MVA-wt at
0.001-1% (Lanes 6-9). 1% corresponds to 1 000 pfu virus. A reaction with MVA-wt alone is shown on lane 10.
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growth of both the parental dMVA-ZG and the D4R-
restored rMVA-YF/D4 the isolates were first expanded
in order to obtain sufficient material for quantitative
tests. For phenotypic analysis, the isolates were sub-
jected to plaque assay on cDF-1 cells. When plaques
were stained with X-Gal to detect parental dMVA-ZG
in the plaque assay, all 12 isolates were phenotypically
free from b-Gal positive parental virus at a test sensitiv-
ity of approximately 1 parental virus among 50 plaques.
In order to further analyze the purity of the primary
isolates, the isolates were subjected to analysis by quan-
titative PCR. As controls, DNA from uninfected cDF-1
cells and DNA from cDF-1 cells infected with wild-type
MVA or with the parental dMVA-ZG were used. In the
PCR, several genomic loci were targeted to identify the
genotypes present in the isolates. Total genomic MVA
DNA was quantified by use of a primer pair that targets
an unrelated gene of the MVA genome-the MVA 173R
(identical with VV B5R gene). In the rMVA-YF/D4 iso-
lates 8.33-8.75 (mean 8.55) log genomic equivalents
(GE)/ml of total genomic MVA DNA were detected
(Table 1). A similar result (8.41) log GE/ml was
obtained for the MVA wild-type control. The virus titer
of the rMVA-YF/D4 isolates ranged from 2.68 × 10
6 to
1.20 × 10
7 TCID50/ml. From the copy number and the
infectious titers, a normal copy-to-infectivity ratio of
117.6 (range 40-235.1) was calculated.
The presence of the gene of interest was measured by
a YFV prME gene specific PCR reaction, where 8.14-
8.55 GE/ml (mean 8.38) were found, consistent with the
total MVA DNA quantification. Expectedly, only back-
ground signals (max. 3.57 log GE/ml) were obtained
with the controls wild-type MVA and dMVA-ZG that
did not contain any YFV sequences.
Two PCRs were performed specifically to detect inter-
mediate structures in the recombinant samples. In the
first analysis that targeted lacZ sequences from the par-
ental virus dMVA-ZG, the isolates rMVA-YF/D4 ranged
from 3.17 to 3.66 GE/ml which is equivalent to the
background (3.58 log GE/ml) measured in uninfected
DF-1 cells. A second analysis targeted the ampicillin
resistance gene to detect intermediate viral genomes
that form during recombination and that still contain
the complete plasmid backbone. Also in this analysis,
the isolates gave results at the background level of the
controls, suggesting that residual intermediate structures
were practically absent in the isolates.
The MVA intergenic D4R/D5R insertion locus
In the present approach, a foreign gene was inserted
into the virus genome downstream of the essential D4R
gene and upstream of the putative promoter of the D5R
gene, as described previously for replicating vaccinia
strains. Commonly used insertion sites for MVA recom-
binants include the HA gene which is supposed to be
silent in MVA, and the genomic deletion III (del3)
region [18,40]. For MVA, insertion into the D4R/D5R
intergenic locus has not been described so far. In order
to assess whether manipulation of this locus affects the
viability of the multifold attenuated MVA, the growth of
the new recombinant MVA was compared to a conven-
tional construct. For this purpose, growth experiments
were performed in parallel with rMVA-YF/D4, and with
a conventionally generated recombinant MVA rMVA-
YF/del3 that contains the analogous foreign sequences
in the del3 locus [31]. With rMVA-YF/D4 that carries
the foreign gene in the D4R/D5R locus, growth rates
and maximal titers were at least as high as with the con-
trol construct where the del3 region was used for inser-
tion (Figure 5), indicating that insertion of foreign DNA
between the MVA D4R and D5R genes does not inter-
fere with virus growth.
Expression of a gene of interest without clonal selection
In conventional selection procedures using non-viral
marker genes and chemicals for selection, clonal purifi-
cation of the recombinant virus is crucial to obtain pure
stocks, because the recombinants are rapidly overgrown
by residual parental virus, once the selective pressure is
removed. In contrast, the dominant host range selection
by rescue of the MVA D4R gene provides a constant
growth advantage to the recombinant over the non-
replicating parental virus. To investigate whether
Table 1 Real-time PCR quantification of different target
sequences in virus isolates obtained by the marker
rescue procedure
Template Total MVA
(1) YF prME
(1) lacZ
(1) AmpR
(1)
rMVA-YF/D4 #1 8.54 8.44 3.33 3.83
rMVA-YF/D4 #2 8.38 8.25 3.17 4.02
rMVA-YF/D4 #3 8.54 8.30 3.47 4.02
rMVA-YF/D4 #4 8.58 8.24 3.37 4.07
rMVA-YF/D4 #5 8.69 8.42 3.37 3.89
rMVA-YF/D4 #6 8.33 8.14 3.45 4.08
rMVA-YF/D4 #7 8.64 8.49 3.66 4.11
rMVA-YF/D4 #8 8.54 8.50 3.61 4.02
rMVA-YF/D4 #9 8.74 8.55 3.48 3.97
rMVA-YF/D4 #10 8.39 8.27 3.54 4.07
rMVA-YF/D4 #11 8.75 8.49 3.42 3.96
rMVA-YF/D4 #12 8.46 8.44 3.56 4.06
Uninfected cDF-1 0.00 0.00 3.58 4.01
Wild-type MVA 8.41 2.62 3.27 3.93
dMVA-ZG 7.46 3.57 7.34 3.93
(1)Results are given in log10 genomic equivalents per ml, and are means of
duplicate measurements
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without any plaque purifications, DF-1 cells were
infected with dMVA-ZG and transfected with the rescue
plasmid pDM-D4R/YF, and the resulting harvest was
serially passaged three times in DF-1 cells without sub-
cloning. For passaging, infections were harvested after 4
days. Crude stocks were prepared, diluted 1:5, and used
in a new round of virus propagation. From each passage,
cell lysates were prepared, and the YFV prME expres-
sion levels were analyzed by Western blotting (Figure 6).
The YFV envelope protein was detectable as a 50 kDa
band already after one virus passage (lane 3). After two
passages (lane 4), expression was similar to the control
rMVA-YF/del3 that had been purified by conventional
clonal selection (lane 8). When the same procedure was
done with a control plasmid that contained the YFV
prME cassette but not the D4R gene as a selectable
marker, E protein expression was undetectable at all
passages (lanes 6, 7). This indicated that the transgene
expression from the transfected plasmid DNA itself was
neglectable, and that the YFV E protein detected by
Western blotting reflected replicating recombinant
MVA virus.
In order to investigate the proportion of recombinant
virus into more detail, the virus from the different pas-
sages was subjected to plaque assay on cDF-1 cells that
equally support growth of the replicating, i.e. recombi-
nant and the defective parental MVA. Plaques were
immune-stained with antisera directed either to yellow
fever virus prME antigen or to vaccinia virus, thereby
discriminating recombinant prME-expressing plaques
from non-expressing MVA plaques.
The percentage of prME-expressing rMVA-YF/D4 pla-
ques was 46% already after the initial recombination,
reaching a plateau after two passages at about 98%
(Table 2).
Discussion
This study describes a method to create recombinant
MVA vectors, based on the principle of dominant host
range selection upon rescue of the viral D4R gene [29].
The presented approach allows for rapid isolation of the
target recombinant, resulting in parental virus-free
recombinant stocks in a single round of plaque purifica-
tion. While generation of recombinants of the highly
attenuated MVA is traditionally more difficult than of
fully replicating vaccinia viruses, the D4R-dominant host
range selection represents a simple and stringent alter-
native to integrate genes of interest into MVA. Tradi-
tional selection methods frequently involve the
introduction of foreign selection marker genes, which
m a yb eu n d e s i r e df o rt h eu s ei nl i v ev a c c i n e s .M a r k e r
genes may be de-stabilized by flanking tandem DNA
repeats [18,41], which however demands for additional
plaque purifications to select for the marker-free
Figure 6 YFV antigen expression from a non-purified virus
stock. Western blot analysis of yellow fever prME protein expression
was performed at different passages of an unselected rMVA-YF/D4
stock, using a polyclonal anti YFV guinea pig serum that detects the
YFV E protein as a ~50 kDa band. The blot shows the primary virus
crude stock following infection of DF-1 cells with dMVA-ZG and
transfection with pDM-D4R/YF (lane 2), and harvest from the first
(lane 3), the second (lane 4) and the third passage (lane 5) of this
stock. In parallel, the plasmid pd3-YFprMEco that lacks the D4R
gene was transfected into dMVA-ZG infected DF-1 cells (lane 6) and
passaged once (lane 7). As a positive control, clonally purified rMVA-
YF/del3 was used (lane 8). Uninfected cells are shown on lane 9.
Table 2 Percentage of transgene expressing virus
plaques after passages without clonal selection
Passage prME Positive Plaques (%)
Primary crude stock 46.3 ± 1.33
1
First passage 92.1 ± 0.23
1
Second passage 98.1 ± 0.78
1
Third passage 97.1 ± 2.86
1
Purified rMVA-YF/del3 99.2
2
1) Mean of two experiments ± SD
2) One experiment
Figure 5 Growth kinetics of the recombinants rMVA-YF/D4 and
rMVA-YF/del3. DF-1 cells were infected with rMVA-YF/D4 and
rMVA-YF/del3 at moi = 0.05. Cells were harvested at the indicated
time points and the viral titers were determined by TCID50 titration.
Mean values ± SEM are shown (n = 6).
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Page 8 of 11genotype. As an alternative to the homologous recombi-
nation method to generate recombinant vaccinia virus,
the cloning and manipulation of the entire vaccinia gen-
ome in a bacterial artificial chromosome (BAC) has
been described [42]. Recently, this method was also
applied to MVA, and was proposed as a rapid approach
for the generation of recombinant MVA [43,44]. While
the BAC technology offers the advantage of targeting
any genomic locus of MVA, the method is dependent
on the use of a helper virus, and results in recombinants
that carry the complete BAC plasmid backbone in addi-
tion to the gene of interest. The BAC construct can also
be designed to favour its excision by spontaneous
homologous recombination [44], requiring however for
additional plaque purifications or serial passage similar
to the previously described marker destabilization. In
contrast, the dominant host range selection procedure
directly results in recombinant viruses without any for-
eign marker sequences by re-introduction of the essen-
tial viral D4R gene as the selection marker.
As a complementing cell line for the defective MVA,
we generated a D4R-expressing avian DF-1 cell line,
because of the advantageous properties of these cells
with respect to virus propagation and plaque formation.
Our approach of engineering the D4R gene into the
cells by retroviral transduction has been applied pre-
viously to a simian cell line [34], and now successfully
to an avian cell line, suggesting that this strategy is
applicable to further cell lines that may be considered
for propagation of MVA. In the present approach, the
complementing DF-1 cell line supported growth of the
defective MVA to levels similar to the wt virus. A D4R
complementing DF-1 cell line by Garber and colleagues
[27] who used a different technique resulted in similar
defective MVA titers, i.e. approximately 5 × 10
7 pfu/ml
at 24 hrs post infection. For use in the dominant selec-
tion procedure, the absolute titer of the defective virus
is not critical. However, the growth kinetics of dMVA
suggest that the expression level of the vaccinia uracil
DNA glycosylase by the cell line cDF-1 was not limiting
for viral replication, hence providing full complementa-
tion of the defective virus.
The approach of selecting recombinant virus by
reconstitution of the viral D4R gene allowed isolation of
clonal recombinant virus in a single round of plaque
purification. The parental defective MVA contains a
lacZ marker cassette that supports screening of descen-
dant recombinant virus. In the initial plating, about 30%
of the plaques appeared blue, indicating that they still
contained parental virus. However, by picking white pla-
ques, all of the 12 isolates were found to be already
pure recombinants without intermediate structures as
analyzed by quantitative PCR.
Because of the constant selection pressure against the
parental defective virus, it is feasible to obtain and
amplify recombinant virus stocks directly after infection/
transfection without any further purification steps. This
simplified method is no option for the production of
well-defined virus stocks, but it represents a powerful
tool e.g. if rapid and efficient transgene expression for
analytical purposes is desired. As an example, we gener-
ated a recombinant virus stock without any plaque puri-
fication, achieving 98% purity in only two blind
passages. The low amount of residual non-expressing
virus suggests that this method is also useful if quantita-
tive assessment of expression levels, e.g. to perform pro-
moter studies. Principally, this type of enrichment
procedure is feasible with any stringent selection mar-
ker. This has been demonstrated previously with the
MVA F13L gene as a selectable plaque size marker [24],
where close to 100% recombinant virus was achieved
after 5 blind passages. However, enrichment procedures
that make use of non-essential genes such as F13L pro-
vide a less stringent selection pressure, because the par-
ental virus is still replicating, though at a reduced
growth rate. On the other hand, deletion of non-essen-
tial host range genes such as K1L provides selective con-
ditions in certain cell systems [18], but growth
restriction of the parental virus is not maintained once
the recombinant virus stock is transferred to avian cells-
the normal substrate for MVA. While recombinant
stocks obtained in this way are bound to be overgrown
by parental virus under standard culture conditions, the
defect in D4R-deleted MVA provides constant selective
pressure in favor of the D4R bearing recombinant virus
in any natural host.
Conclusions
The D4R dominant host range selection represents a
quick and stringent method to generate recombinant
MVA viruses. The method represents an alternative to
current selection techniques that rely on additional mar-
ker genes, chemical agents, and multiple rounds of pla-
que purification. In contrast to traditional homologous
recombination protocols and to the recently described
BAC cloning procedure, the less laborious D4R-domi-
nant host range selection approach by principle does
not require foreign marker genes, resulting in MVA
recombinants that are free from marker gene sequences
and that thus meet the state-of-the-art requirements for
use as live vaccines.
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